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ABSTRACT 
FUNCTIONAL SELECTIVITY AT THE D1 DOPAMINE RECEPTOR: STUDIES USING 
SKF83959 
(Under the direction of Richard B. Mailman, Ph.D.) 
 
The goal of this project was to study the existence unique signaling mechanisms of D1 
receptors in the context of the phenomenon called receptor functional selectivity. This theory 
holds that agonists may activate functional pathways linked to a single receptor selectively. 
My first aim was to improve upon an existing adenylate cyclase assay, increasing 
productivity and decreasing cost. The second aim of this work was to test the hypothesis that 
D1 receptors could stimulate phospholipase C activity and adenylate cyclase. This study 
characterized members of several structural families of D1 agonists, using these two 
functional endpoints in both stably transfected HEK293 cells and rat striatal tissue. My data 
show that as expected, none of the D1 agonists tested activate phospholipase C. These data 
are inconsistent with the hypothesis that D1 receptors activate phospholipase C as a signaling 
mechanism. These data have important implications for understanding D1 receptor signaling.  
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PREFACE 
I have prepared my thesis in accordance with the guidelines set forth by the Graduate 
School of the University of North Carolina. This thesis consists of a general introduction, two 
research chapters of original data, and an overall conclusion chapter. Each data chapter 
includes an abstract, introduction, methods and materials, results and discussion sections. A 
complete list of the literature cited throughout the thesis has been appended. References are 
listed in alphabetical order and follow the format of The Journal of Pharmacology and 
Experimental Therapeutics. 
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CHAPTER 1. SCOPE OF THIS WORK 
DOPAMINE SYSTEMS 
The CNS dopaminergic system plays a critical role in cognition, learning, motor 
control, reward and attention. Pharmacologically, this has been an attractive therapeutic 
target for schizophrenia, Parkinson’s disease, and cognitive enhancement, whereas it also is a 
critical system in drug abuse because of the modulating activity of the nucleus accumbens, 
the reward center of the brain. The dopaminergic system is grossly divided into four major 
systems, the mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular pathways 
(Figure 1.1). The mesolimbic pathway begins at the midbrain, specifically the ventral 
tegmental area (VTA), and terminates in the nucleus accumbens and related structures. The 
mesocortical pathway extends from the VTA to the frontal cortex, playing a key role in 
cognition and reasoning. The nigrostriatal pathway (projecting from the substantia nigra to 
the striatum) is crucial for motor and postural control, and is the key focus of pathology and 
therapeutics of Parkinson’s disease (PD). Degeneration of substantia nigra dopaminergic 
neurons of the nigrostriatal pathway leads to the motor dysfunction associated with PD, but 
interestingly, symptoms occur only when 60% or more of the neurons have died. The 
tuberoinfundibular pathway is intrinsic in the hypothalamus, and a portal system from 
median eminence neurons modulates prolactin secretion from the anterior pituitary gland. 
Collectively, these pathways are crucial in understanding the mechanisms of effective 
treatment and side-effects, in addition to off-target effects of therapeutics and potential 
functional selectively mechanisms.  
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Figure 1.1. Schematic of brain dopamine pathways. 
DOPAMINE RECEPTORS 
Dopamine receptors, members of the G protein-coupled receptor (GPCR) superfamily 
(also dubbed 7-transmembrane receptors, 7TM) fall into two sub categories, D1-like and D2-
like receptors. D1-like receptors include the D1 and D5 subtypes that are positively coupled to 
adenylate cyclase via heterotrimeric G protein Gs/olf activation. The activation of adenylate 
cyclase leads to phosphorylation of protein kinase A (PKA) and subsequently protein 
phosphatase 2A (PP2A) and dopamine- and cyclic AMP-regulated phosphoprotein (DARPP-
32). These effectors regulate other receptors, ion channels and transcription factors. D2-like 
receptors consist of the D2, D3 and D4 receptor sub-types that couple to Gi/o G proteins, 
negatively modulating cAMP generation, yet positively stimulating arachidonic acid (AA) 
synthesis and ERK1/2 phosphorylation, in addition to affecting ion channels and downstream 
transcription factors.  
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Although the two D1-like receptors are structurally very similar, there are some key 
variations in localization. D5 receptors are scarcely expressed, if at all, in the human striatum, 
whereas D1 receptors are highly expressed. In other areas like the hippocampus and 
prefrontal cortex, both receptors play important roles, including in working memory 
(Bergson et al., 1995; De Keyser, 1993). D1-like receptors are exclusively located post-
synaptically. 
In addition to localized expression differences, there is also interesting evidence of 
distinct signaling between the two subtypes. Studies using HEK293 cells demonstrated that 
when the γ7 subunit of the heterotrimeric G protein is degraded, D1-mediated adenylate 
cyclase signaling is abrogated, whereas D5 receptor signaling remains in tact (Wang et al., 
2001). There also may be differences in DARPP-32, ERK1/2 and GluR1-AMPA signaling 
between the D1-like receptors. D1 receptors, and to a much lesser extent D5, were found in 
rats to be differentially modulated with SKF 83822 (O'Sullivan et al., 2008). Interestingly, 
this particular compound is purported to signal exclusively through phospholipase C rather 
than via adenylate cyclase (O'Sullivan et al., 2004). These data are based on behavioral 
assessments alone, however, and have not yet been replicated in an in vitro system. Aspects 
of this thesis explore some of these relevant mechanisms. 
PARKINSON’S DISEASE 
Parkinson’s Disease is the second most common age-related neurodegenerative 
disorder, and affects all ethnic groups, although Asians and African blacks have a lower 
incidence, whereas higher rates are found in Caucasians (Zhang and Roman, 1993). Most 
studies indicate about 60% or more of the cases occur in males.  
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Parkinson’s disease is characterized by three types of symptoms: primary motor, 
secondary motor and non-motor. Primary motor signs are characterized by resting tremor, 
bradykinesia, rigidity and postural instability, and the diagnosis of the disease is made on the 
basis of the occurrence of several of these cardinal signs. These are the most common and 
notable signs of Parkinson’s disease, however many patients experience secondary motor 
symptoms that can include fatigue, speech control, loss of facial expression, micrographia 
and difficulty swallowing. Additional non-motor symptoms that can be particularly difficult 
for a patient include depression, constipation, pain, dementia, and memory difficulties. 
Although currently therapies address the motor domain well, the non-motor symptoms are 
more difficult to treat. 
Toxicology and Parkinson’s disease 
Exogenous toxicants have been implicated as a playing a role in a subset of 
Parkinson’s disease cases (Ascherio et al., 2006). The first example of this toxicant-induced 
neurodegeneration came from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Davis 
et al., 1979; Langston et al., 1983). MPTP itself is relatively non-toxic, but when taken up by 
the brain monoamine oxidase B located in astrocytes form the toxic metabolite 1-
methylphenylpyridium (MPP+). As with Parkinson’s disease, MPP+ kills dopamine neurons 
located in the pars compacta of the substantia nigra (SNpc). Parkinson’s-like symptoms such 
as tremor, bradykinesia, and postural instability rapidly occur.  
This is one of many xenobiotics that have been hypothesized to play a role in some 
cases of Parkinson’s Disease (Gerlach et al., 1991). Pesticides have long been suspected of 
playing a role in the etiology of Parkinson’s disease, largely due to studies based on MPTP 
exposure and the observed chemical similarity to some pesticides. Epidemiological studies 
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have suggested positive associations with long-term exposure to pesticides such as paraquat 
(Liou, 1997), rotenone (Kamel et al., 2001), and organophosphates (Firestone et al., 2005; 
Wechsler et al., 1991). Rat studies using rotenone and MPTP have shown clear causation of 
parkinsonism-like symptoms (Caboni et al., 2004; Helmuth, 2000). Nonetheless, it remains 
unclear to what degree, if any, pesticides facilitate or plays a causal role in the development 
of Parkinson’s disease.  
In addition to pesticides, a recent study by Stepens et al. (2008) has suggested a 
potential role for manganese. The study found that people using methcathinone, a 
psychoactive drug of abuse, exhibited extrapyramidal syndrome (EPS). The methcathinone 
preparations were found to be tainted with high levels of manganese and MRI results showed 
hyperintensity in the globus pallidus and substantia nigra (Stepens et al., 2008). The patients 
did not recover from EPS following discontinuation of methcathinone, suggesting 
irreversible damage to the globus pallidus and substantia nigra. This hypothesis is supported 
by work in a rodent model studying inhalation of divalent and trivalent. Mice exhibited signs 
of akinesia, postural instability and action tremor, while post-mortem analysis showed 
roughly a 70% decrease in tyrosine hydroxylase positive neurons in the SNpc (Ordoez-
Librado et al., 2008).  
Genetics of Parkinson’s 
Several genes have been linked to Parkinson’s disease, but to date, these seem to play 
a role only in rare, early-onset, familial forms of the disorder. Parkinson’s disease has been 
linked to dysfunction of α-synuclein (Polymeropoulos et al., 1997). Although all of the 
details of α-synuclein function as yet are unclear, epidemiological studies have pointed 
towards the need for more study in the context of neurodegenerative disorders. Chandra et al. 
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provided the first clue as to its function. Using transgenic mice, expression of α-synuclein 
restores neuroprotection following the deletion of cysteine-string protein-α (CSPα). The 
function of CSPα is not replaced by α-synuclein, instead it acts as a downstream effector in 
the pathway by binding to phospholipids in an α-helical conformation. These data provide 
specific evidence of in vivo function of α-synuclein which prevents neurodegeneration of 
presynaptic neuronal processes (Chandra et al., 2005). These data are complicated by the 
inability of endogenous α-synuclein to prevent lethality in CSPα knockout mice, but the 
specific rescue of neurodegeneration and known association between CSPα and α-synuclein 
reinforces the necessity of further mechanistic studies. 
An additional genetic role has been implicated for E3 ligase parkin, involved with the 
ubiquitin-proteosome system, which when omitted causes autosomal recessive juvenile 
parkinsonism (Kitada et al., 1998). It has been posited that mutations in this protein lead to 
misfolding and aggregation of proteins which facilitate the death of SNpc dopaminergic 
neurons (Hattori and Mizuno, 2004). It is also interesting to note that Lewy bodies 
(commonly found in neurons of Parkinson’s disease and Alzheimer’s patients) are 
immunoreactive to ubiquitin. This perhaps reinforces the role of parkin and more generally 
dysfunction of protein degradation in the pathology of Parkinson’s disease. Other studies 
have investigated roles for other parkin isoforms, specifically park7, however their incidence 
is significantly less than that of park2, the main known culprit in parkin-related Parkinson’s 
disease (Hedrich et al., 2004). 
Current pharmacotherapy of Parkinson’s 
The gold standard for the current treatment of Parkinson’s disease is levodopa (L-
DOPA), a prodrug for dopamine that permits remaining dopamine neurons to produce excess 
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amount of dopamine in terminal fields. Levodopa is always used with a peripheral 
decarboxylase inhibitor (carbidopa or benserazide) to decrease peripheral adrenergic and 
dopaminergic side effects. Although dramatically effective for some years, long-term 
treatment with L-DOPA eventually leads to a decline in therapeutic benefit, although this 
may be attenuated somewhat by the use of adjuvants such as MAO-B (monoamine oxidase) 
inhibitors (selegiline or rasagiline), COMT (catechol-o-methyltransferase) inhibitors 
(entacapone or tolcapone) and other agents like NMDA (N-methyl-D-aspartic acid) 
antagonists (amantadine). Despite its effectiveness, levodopa therapy tends to eventually lead 
to debilitating side effects, especially dyskinesias, as well as loss of effectiveness expressed 
as “on-off” effects. There have been many direct dopamine agonists that have been used in 
PD, and two currently are widely used: pramipexole (Mirapex) and ropinirole (Requip). 
These target the D2-like receptors, and although having a useful place, they are only 
fractionally better than placebo relative to levodopa. The use of these D2 agonists is thought 
to smooth out the pattern of target neuron effects, and as an adjunct therapy to levodopa 
decrease side effects like dyskinesia. They have a narrow dose-response relationship, 
however, and can cause nausea and vomiting, as well as psychosis. This occurs largely via 
the same mechanism by which they act therapeutically (i.e., activation of D2-like receptors).  
D1 agonists and Parkinson’s disease 
The field has struggled with a conundrum: levodopa, accepted to work via indirect 
activation of all dopamine receptors, is dramatically effective, whereas even high potency D2 
agonists have only modest effects (Mailman et al., 2001). This suggests that D1 activation is 
critical, alone or in concert with D2 activation. Many of the side effects of levodopa (like 
dyskinesia) are thought to be due to long-term effects of pulsatile receptor activation 
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(Mailman and Huang, 2007). This pulsatility, and the resulting dyskinesias, is probably the 
result of the short half-life of levodopa, its indirect mechanism of action, and the 
continuingly fewer dopamine neurons left to process the levodopa. In theory, therefore, the 
use of dopamine agonists should be beneficial because one could better control the degree 
and timing of receptor activation.  
Currently, no centrally active D1-selective agonist is approved for human clinical use, 
but there has been much experimental work addressing this paradox. Early data suggested 
that D1 agonists were not involved in dopamine-induced amelioration of PD symptoms. 
These studies were, however, problematic, principally due to the fact that the available D1 
agonists like SKF38393 were only partial agonists (Barone et al., 1986). Thus, an early study 
showed little to no effect on tremor while inducing bradykinesia in the marmoset animal 
model (Close et al., 1985). While SKF38393 has excellent potency for the D1 receptor, its 
intrinsic activity for adenylate cyclase activation is less than half that of dopamine. For these 
reasons, the common view in the field for many years was that all therapeutic actions of 
levodopa and agonists were mediated via D2 receptors (Cederbaum and Schleifer, 1990). 
This idea was challenged when dihydrexidine, the first full D1 agonist (Brewster et 
al., 1990; Lovenberg et al., 1989; Mottola et al., 1992) became available. Dihydrexidine had 
dramatic antiparkinson effects in MPTP-treated monkeys (Taylor et al., 1991). Dihydrexidine 
almost completely decreased symptoms as assessed by a parkinsonian summary score 
(factors included were tremor, food response, poverty of movement, etc). The major 
limitation of dihydrexidine is its extremely short half-life (on the order of minutes in 
humans). Nonetheless, in a limited human study of Parkinson’s patients, dihydrexidine 
caused major, but transient improvement in 1 out of 4 patients, but because of the need to 
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deliver high bolus doses, was limited by hypotension, its primary side effect (Blanchet et al., 
1998).  
Subsequent to these studies, a second D1 full agonist A-77636 was discovered and 
also shown to have dramatic acute antiparkinson effects in a marmoset MPTP-induced model 
of parkinsonism (Kebabian et al., 1992). It, however, was limited by a rapid tolerance (Asin 
et al., 1994) that might be a result of prolonged internalization of the D1 receptor caused by 
this drug (Ryman-Rasmussen et al., 2007). After abandoning A77636, Abbott developed a 
new compound A-86929 that is a structural analog of dihydrexidine (Michaelides et al., 
1995) with very similar pharmacological properties. It was shown not to cause the tolerance 
seen with A-77636 (Asin et al., 1997). Like dihydrexidine, it was also very short-acting and 
not orally available, so a prodrug form, ABT-431 was developed to overcome these 
pharmacokinetic problems (Shiosaki et al., 1996). ABT-431 was tested in humans, and is the 
only drug to have efficacy that equals levodopa (Rascol et al., 1999; Rascol et al., 2001), and 
possibly a better side effect profile (Rascol et al., 1999). These and other data have made the 
potential of D1 agonists in treating Parkinson’s disease clear, although a variety of 
pharmacological (seizures, hypotension) and pharmaceutical (chemical instability, oral 
availability, short duration of action) problems have yet prevented the approval of a drug. 
Promisingly, these problems seem to be idiosyncratic to specific drugs, leaving open the 
possibility of discovery of a successful drug. This summary underscores the pharmacological 
and toxicological importance of understanding D1-related mechanisms.  
Other potential beneficial actions of D1 agonists 
The importance of this thesis is underscored by another promising use of full D1 
agonists, that is, the treatment of cognitive deficits. The cortical density of D1 receptors is up 
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to 10 fold higher than that of D2 receptors, pointing to their role in the mesocortical pathway 
(Hall et al., 1994; Lidow et al., 1991). More specifically, the prefrontal cortex has been 
shown to play a critical role in working memory, a subcategory of short-term memory 
(Goldman-Rakic, 1998; Goldman-Rakic et al., 2000). In young human subjects, pergolide 
was shown to improve delayed matching performance when compared with placebo, further 
proof for the role D1 agonists have in improving working memory (Muller et al., 1998). 
Indeed, as the first full D1 agonist, dihydrexidine was a major tool in showing the importance 
of D1 activation (Arnsten et al., 1994; Johnson et al., 1995; Schneider et al., 1994; Steele et 
al., 1996; Steele et al., 1997). This again underscores the importance of understanding the 
relevant mechanisms of D1 agonists. 
FUNCTIONAL SELECTIVITY 
Classical pharmacology holds that the efficacy of a ligand is constant across all of its 
effectors. Although this certainly holds true for the endogenous ligand and many synthetic 
compounds, exceptions to this theory are now widespread. The idea that some ligands may 
signal differentially (e.g., as a full agonist at one pathway, a partial agonist at a second, and 
even an antagonist at a third) was given many names (e.g., agonist-directed trafficking, 
differential engagement, biased agonism, protean agonism, stimulus trafficking, etc.), but the 
field has now settled on the term functional (Urban et al., 2007a), as first coined by our lab 
(Lawler et al., 1994).. Data showing functional selectivity have been extant for more than a 
decade, but the dogma of classical pharmacology hindered the interpretation of compounds 
having such differential signaling properties. Despite predictions that functional selectivity 
might exist (Jim et al., 1985; Roth and Chuang, 1987), publication of such findings was 
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difficult, as reviewers often assumed the data were experimental artifacts caused by off-site 
receptor or non-receptor actions within a functional assay. 
At present, much of the pharmacology community has grown to appreciate the 
existence of functionally selective compounds. As an example, studies of the novel atypical 
antipsychotic drug aripiprazole have shown it to have significantly less potency for MAP 
kinase stimulation when as compared to [3H] arachidonic acid (AA) release in CHO-D2L cells 
(Urban et al., 2007b). This work showed a significant difference in relative potency for two 
distinct effector pathways, providing important and convincing evidence of a functionally 
selective compound approved for therapeutic use in humans. Other examples include two 5-
HT2C ligands. The first called bufotenin has been found to have full agonist properties for AA 
release but partial agonist properties for inositol phosphate (IP) accumulation. Conversely, 
m-trifluoromethylphenylpiperazine (TFMPP) showed full agonist intrinsic efficacy for IP 
accumulation, but only partial agonist properties for AA release (Stout et al., 2002). These 
are a few of many recent reports supporting the theory of functional selectivity. Although 
most research has focused on in vitro signaling models, more work now and in the future will 
tackle the task of providing convincing in vivo results supporting functional selectivity. The 
importance of functional selectivity to toxicology and pharmacology is illustrated in the 
cartoon in Figure 1.2. 
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Figure 1.2. Functional selectivity and its implications in therapeutic and toxic actions of drugs. 
Adapted from Mailman (2007) 
Although the overlying theory and data support the notion that drugs can have 
relative intrinsic efficacy, the mechanisms by which this occurs remain elusive. There are 
two schools of thought that seek to describe functional selectivity more precisely: 
conformational induction and drug-active state selection. The importance of this distinction 
lies with applying the theory of functional selectivity to the drug development process. A 
greater understanding of these mechanisms would certainly lead to better therapeutic 
exploitation of functional pathways.  
Conformational induction posits that ligands possess the ability to affect unique 
conformational change within a receptor upon binding. This agonist-receptor complex then 
retains the ability to couple to particular G proteins, scaffolding proteins and GRKs, etc. This 
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complex, when compared to another ligand of a different chemical family, may be quite 
different due to the unique mode of agonist binding. In very simplistic terms, the theory of 
induction is dependent on specific ligand properties to lead to a functionally selective 
outcome.  
Testing of the sub-theories of functional selectivity remains difficult due to problems 
with GPCR crystallization. Bioluminescence resonance energy transfer (BRET) has proven 
to be an important technique when studying conformation changes in living cells. A powerful 
study by Swaminath et al. (2004) used the β2 adrenergic receptor to label Cys265 with a 
fluorescent dye which resides in the third intracellular loop, an area thought to be important 
for G protein coupling. The authors demonstrated that different catecholamines induce a 
sequence of two different conformational changes, a rapid and a slow change in the receptor. 
Moreover, dopamine was found to induce only a rapid change in conformation leading to 
adenylate cyclase activation, but not receptor internalization. This compared to 
norepinephrine and epinephrine, which induced both rapid and slow responses, leading to 
both adenylate cyclase and receptor internalization. These data strongly support the notion of 
agonist-induced conformational changes, but these a great deal of research remains with 
other receptor models and families to allow understanding of the intricacies of functional 
selectivity. 
Drug-active state selection hypothesizes that there is pre-coupling of G proteins, 
scaffolding proteins, and receptor that creates unique conformational states each linked to 
activation of a signaling pathway. Some ligands can select for only some of these active 
states. In contrast to induction, selection posits that the mechanism of functional selectivity is 
entirely dependent on populations of unique receptor-effector complexes. Much of this 
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evidence was initially derived from the observation that GPCRs couple to G proteins in the 
absence of agonist, accounting for basal activity of the receptor. This, together with studies 
demonstrating coupling of multiple G proteins to a given receptor has strengthened the 
logical possibility of sub-populations of receptors that may be more apt to bind a given 
ligand (Kenakin, 1995). Moreover, the use of over-expression in vitro models may lead to G 
protein promiscuity and thus the creation of an artifact of active-state receptors. It should be 
noted however that these two theories for the underlying modality of functional selectivity 
need not be mutually exclusive, although one may predominate.  
The ultimate goal of studying functionally selective drugs is to learn how to decrease 
unwanted side effects while retaining clinical efficacy. As noted earlier, aripiprazole has 
interesting functionally selective properties and is currently used in patients with 
schizophrenia, bipolar disorder and depression. To this end, a major effort is underway to 
study in vivo mechanisms. The use of animal models engineered to express designer 
receptors called DREADDs (designer receptors exclusively activated by designer drugs) has 
begun (Nawaratne et al., 2008), in addition researchers are using more extensive screening of 
compounds and neuronally derived cell lines. Given the complex nature of cellular signaling, 
particularly neuronal, the constant improvement of techniques and theories will surely 
unravel the puzzle.  
GOALS OF THIS THESIS 
The overall objective of my work was to study D1 signaling mechanisms and test the 
specific hypothesis that some D1 agonists are functionally selective in their activation of 
adenylate cyclase versus phospholipase C pathways. My thesis accomplished these goals via 
two specific aims. 
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Aim 1. Develop a streamlined, highly sensitive and high-throughput method for 
measuring adenylate cyclase activity.  
Because my proposed work involved adenylate cyclase assays as a major signaling 
pathway, improvements were made to existing assays that then accelerated my work on Aim 
2. The improved method cut costs and assay time, but preserved the sensitivity and 
reproducibility of the assay.  
Aim 2. Investigate the functional selective signaling properties of various classes of 
D1 agonists. 
To assess the functional selectivity of D1 agonists, I utilized the functional endpoints 
adenylate cyclase and phospholipase C. Different classes of D1 agonists including 
phenylbenzazepines (SKF83959, SKF83822, SKF38393), isochromans (A77636) and rigid 
fused ring compounds (dihydrexidine) were used to discriminate potency and intrinsic 
activity.  
 
  
CHAPTER 2:  
RAPID, SEMI-AUTOMATED, AND INEXPENSIVE RADIOIMMUNOASSAY 
OF CAMP: APPLICATION IN GPCR-MEDIATED ADENYLATE CYCLASE 
ASSAYS 
ABSTRACT 
Cyclic AMP (cAMP) is an important signal transduction second messenger that is 
commonly used as a functional mirror on the actions of G protein-coupled receptors that can 
activate or inhibit adenylate cyclases. A radioimmunoassay for cAMP with femtomole 
sensitivity was first reported by Steiner more than 30 years ago, and there have been several 
subsequent modifications that have improved this assay in various ways. Here we describe 
additional improvement to existing methods that markedly improve speed and reduce cost 
without sacrificing sensitivity, and is also adaptable to analysis of cGMP. The primary 
antibody is coupled directly to magnetic beads that are then separated from unbound marker 
using filtration on microplates. This eliminates the need for a secondary antibody, and 
markedly increases throughput. In addition, we report a simple, reproducible, and 
inexpensive method to make the radiomarker used for this assay. Although still requiring the 
use of radioactivity, the resulting method retains a high degree of accuracy and precision, and 
is suitable for low-cost high-throughput screening. Use of aspects of this method can also 
improve throughput in other radioimmunoassays. 
 
[Citation: Brown JT, Kant AC, Mailman RB. Rapid, semi-automated, and inexpensive 
radioimmunoassay of cAMP: Application in GPCR-mediated adenylate cyclase assays. 
J Neurosci. Meth. (in press).] 
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INTRODUCTION 
Cyclic AMP (3’,5’-cyclic adenosine monophosphate; cAMP) is a key second 
messenger involved in numerous intracellular signaling pathways (Antoni, 2000; McPhee et 
al., 2005). Production of cAMP is controlled by the membrane-bound family of adenylate 
cyclases (ACs) that convert adenosine triphosphate to cAMP. The activity of most of the 
ACs is regulated by heterotrimeric GTP-binding proteins (e.g., Gαs/olf, Gαi/o) that directly 
interact with the intracellular region of GPCRs and can both increase or decrease enzyme 
activity (Hanoune and Defer, 2001). In addition, phosphodiesterases can catalyze the 
degradation of cAMP (Weishaar, 1986). 
The measurement of adenylate cyclase activity can be accomplished using 
radiometric assays that follow the incorporation of a radioactive precursor into cAMP 
(Salomon, 1979; Schulz and Blum, 1985). More commonly, however, a variety of methods 
that quantify cAMP have been used both for assessment of adenylate cyclase activity, as well 
as for measuring tissue content of cAMP or breakdown of this second messenger. A major 
advance for the field was the development by Steiner et al. (1972) of a radioimmunoassay 
(RIA) for cAMP that offered a high degree of sensitivity and specificity that was soon 
improved by Harper and Brooker (1975). Attempts at automating this assay actually led to a 
commercial instrument (Brooker et al., 1976), but this proved unwieldy.  
More recently, other methods for quantifying cAMP have used different radiometric 
or reporter gene strategies (Williams, 2004). Recently developed radiometric assays such as 
Flashplate technology (NEN/Perkin Elmer) and scintillation proximity assays (SPA, 
Amersham Biosciences) are based on the competition of [125I]-labeled cAMP and analyte 
cAMP, resulting in the production of light when the labeled compound is in close proximity 
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to a solid scintillant surface. These assays are convenient and reproducible, but are often 
more expensive than traditional radiometric methods and generally speaking less sensitive. 
Reporter-gene assays utilize cell lines expressing reporter enzymes such as luciferase, green 
fluorescent protein (GFP), and β-lactamase. Levels of intracellular cAMP are detected via the 
expression level of a reporter gene that is modulated by transcription factor binding to 
upstream cAMP response elements (CRE). Reporter-gene assay are generally less expensive 
than the radiometric assays discussed above, however, they are often plagued by high false-
positive hit rates. Several novel, non-radiometric methods to quantify cAMP also have 
recently become available. These assays involve the use of luminescent proximity 
(ALPHAScreen®) (Ullman et al., 1994), enzyme complementation technology (DiscoveRx, 
HitHunterTM EFC), or electrochemiluminescence (Meso Scale Discovery) to detect receptor-
mediated changes in intracellular cAMP. Each method is readily compatible with automated 
high throughput screening (HTS), and often demonstrates a high level of sensitivity, but 
requires a high degree of instrumentation to maximize throughput putting it beyond the reach 
of most academic labs. 
For this reason, the RIA (or to a lesser extent, protein binding assays using PKA-
enriched tissue) remains the most widely used technique. There has been a recent report 
detailing an improved procedure for this RIA (Post et al., 2000). Indeed, there are 
commercial kits available (e.g., Amersham Biosciences) that utilize secondary antibody 
bound to magnetizable polymer beads, and are separated by magnetic separation or 
centrifugation. Using the dopamine D1 receptor as a model system, we now describe 
improvements to this procedure that decrease the number of experimental steps, the assay 
time, and the assay cost, without sacrificing accuracy or precision. In addition, we describe a 
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rapid method for the routine production of the [125I]-labeled cAMP derivative that is used as 
the radiomarker in this RIA.  
EXPERIMENTAL PROCEDURES AND RESULTS 
Materials and reagents 
Dihydrexidine was synthesized according to procedures previously published 
(Brewster et al., 1990). Acetic anhydride, dopamine, IBMX, pargyline, propranolol, 
SKF38393, and triethyleneamine, and 2’-O-monosuccinyladenosine 3’:5’ monophosphate 
tyrosyl methyl ester (ScAMP-TME) were purchased from Sigma-Aldrich (St. Louis MO). 
HEPES was obtained from Research Organics, Inc. (Cleveland OH). Dulbecco’s modified 
eagle’s media (DMEM), penicillin/streptomycin, and fetal bovine serum (FBS) were 
purchased from Gibco/Invitrogen. UniFilter-96 GF/B RIA filter plates, Microscint™ 20, and 
Na125I were purchased from Perkin-Elmer (Waltham, MA, USA). Donkey anti-goat antibody 
was purchased from Jackson ImmunoResearch (West Grove, PA, USA). Amine terminated 
BioMag® beads were purchased from Polysciences, Inc. (Warrington, PA, USA), and pre-
conjugated Biomagnetic Particles (BMP) to donkey anti-goat secondary was obtained from 
Rockland, Inc (Gilbertsville, PA, USA).  
Sample Generation and storage 
cAMP is a relatively heat and acid stable compound that does not require special 
storage. The following procedure illustrates a common way that samples are generated from 
a GPCR-based cellular system, but the assay that follows can be used for almost any matrix.  
Cell culture: Human epithelial kidney (HEK-hD1) cells transiently transfected with 
human D1 dopamine receptor using pcDNA3.1 vector (Invitrogen) cells were maintained 
using Dulbecco’s Modified Eagles’ Medium with 50 U/mL of penicillin, 50 µg/mL of 
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streptomycin (Gibco), and supplemented with 10% fetal bovine serum at 37°C, 5% CO2. 
Saturation binding experiments with the D1-selective antagonist [3H]SCH23390 using 
membrane homogenates provided a Bmax of approximately 4.5 pmol/mg protein.  
Cell membrane adenylate cyclase assay: Assay buffer was prepared containing 100 
mM HEPES, 4 mM MgCl2, 2 mM EDTA, 100 mM NaCl 10 µM pargyline, 500 µM IBMX, 
0.1% ascorbic acid, pH 7.4. Drug dilutions were prepared at a range of 10-4 to 10-10 M with 
three replicates per drug treatment. Diluted drugs, ATP (2 mM), GTP (5 µM), 
phosphocreatine (20 mM), creatine phosphokinase (185 U/tube) and propranolol (100 µM to 
block endogenous β1-adrenergic receptors) were added in a total volume of 100 µL in each 
well of a 48-well plate. The reaction was initiated by addition of HEK-hD1 cell membranes. 
Plates then were vortexed briefly, and incubated at 30°C for 15 min. The reaction was 
terminated with 500 µL 0.1 M HCl, and stored at 4°C. Prior to transferring samples for the 
RIA, plates are centrifuged for 5 min at 2,500 g using a RC-3B centrifuge from Sorvall 
Instruments (H2000B rotor) to pellet cellular debris. Plates will keep indefinitely at 4°C 
following the assay.  
cAMP Radioimmunoassay 
Iodination reaction 
The radiomarker 2′-O-[4-monosuccinyladenosine 3′:5′-cyclic monophosphate-3-
[125I]iodotyrosyl methyl ester (hereafter termed ([125I]cAMP-ScTME).was first reported by 
Steiner et al. (Steiner et al., 1972) can be purchased commercially. For laboratories that will 
run a reasonable number of such assays, it is technically simple and inexpensive to 
synthesize this in the laboratory as outlined below. The overall reaction scheme as outlined 
by Steiner and coworkers (Steiner et al., 1972) is shown in Figure 2.1. 
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Figure 2.1: Reaction scheme for synthesis of 2′-O-[4-monosuccinyladenosine 3′:5′-cyclic 
monophosphate-3-iodotyrosyl methyl ester. Conditions described in Methods (molar excess of 
precursor) favor the formation of the monoiodinated product (see Figure 2.2). 
The following reagents and buffers are required: 
• 0.5 M phosphate buffer, pH 7.6. We usually make this by titrating 15 mL of 0.5 M 
K2HPO4 with ca. 1.5 mL of NaH2PO4 to pH 7.6.  
• 0.05 M phosphate buffer (pH 7.6). This is prepared by adding 10 mL of the 0.5 M 
phosphate to 90 mL H2O.  
• Carrier-free Na125I. We usually use 2 or 5 mCi. If more than 5 mCi is used, the amount of 
precursor should be increased proportionally,  
• Precursor ScAMP-TME [2’-O-monosuccinyladenosine 3’:5’ monophosphate tyrosyl 
methyl ester; Sigma M2257]. From the 1 mg commercial size, we make 1-1.5 mL of a 
stock solution containing 0.1 mg/mL of distilled water. Aliquots (50 µL) are added to 
microfuge tubes, labeled, and frozen at -20 C. A single aliquot is used for each 
radioiodination. The frozen precursor appears stable for several years.  
• Chloramine-T: (20 mg/10 mL 0.05 M PO4). 
• Sodium metabisulfite: (24 mg/10 mL 0.05 M PO4). 
The reaction procedure is as follows. Briefly, 80 µL of the 0.5 M phosphate buffer pH 
7.6 is added directly to the container in which carrier-free Na125I (Perkin Elmer) arrives. We 
usually iodinate with 5 mCi, but this can be varied. Then, the whole content of one of the 
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thawed aliquots of ScAMP-TME (5 µg/50 µL H2O) is added, the cap screwed back on, and 
the vial mixed on a vortexer for 15 sec. Following this, Chloramine T (100 µL of 2 mg/mL 
solution) is added, and timing begun as the mixture is vortexed. After ~45 sec, the reaction is 
terminated by addition of sodium metabisulfite (200 µL of 2.4 mg/mL solution). [Safety 
note: Unreacted 125I is potentially volatile, and a potential health hazard. The use of 
concentrated (0.5 M) phosphate buffer insures that the reaction solution does not become 
acidic, a condition favoring the liberation of molecular iodine. In addition, this reaction is 
done in a chemical hood.] 
Purification of iodinated product 
It is necessary to separate the monoiodinated cAMP-ScTME from free iodine, 
diiodinated cAMP-ScTME and other minor by-products. Although this can be done using 
batch chromatography with reverse phase Sep-Pak cartridges (Oehlenschlager et al., 1990), 
we have dedicated an archaic isochratic HPLC system and fraction collector for this purpose. 
The total reaction volume (~500 µL) is injected using a Rheodyne 7125 Injector (500 µL 
loop). The isocratic separation (0.8 mL/min) uses a C18 reverse phase column (Inertsil ODS 
2-5 µm, Metachem Technologies). The column effluent is collected by a fraction collector 
(0.5 min samples), and a typical chromatogram is shown in Figure 2.2. As noted above, 
unreacted 125I is a potential health hazard, and for the separation, 100 µL of 0.1 M sodium 
hydroxide is added to the first ten tubes on the fraction collector to insure that all unreacted 
iodine remains in the form of soluble sodium iodide rather than molecular iodine.  
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Figure 2.2: Chromatogram of radioiodination. [Bottom tracing] shows injection of cAMP-Sc-TME 
precursor alone using conditions as described in Methods using 254 nm UV detection. The solvent 
front emerges at ~ 2 min, and the precursor elutes at ~ 6min. The signal in the solvent front and a 
detectable shoulder on the major peak is consistent with the 95% purity estimated by the supplier. 
[Top tracing] Actual results from a radioiodination. The monoiodinated product that is 
immunologically recognized elutes at ~28 min, and is the fraction to be collected and used for the 
RIA. This fraction contains from 60-70% of the radioactivity in a typical reaction. The fraction 
eluting at ~40 min also contains significant radioactivity (10-20%), and is presumably the 
diiodinated form. These two peaks account for ~80% of the total radioactivity injected, with the 
remainder of the radioactivity largely eluting in the solvent front (representing unreacted iodine or 
highly polar reaction by-products).  
The radioactivity is estimated using a hand-held radioactivity detector (or one can 
count 1 µL aliquots), and the tubes with the highest radioactivity (usually 3-4 tubes) are 
pooled together, diluted with 1.5 volumes of methanol, and then divided into two or more 
aliquots for storage at -20°C. Under these conditions, the marker is usable for a minimum of 
four months, although there is a significant loss of material due to decay.  
Preparation of primary antibody conjugation to amine-terminated beads 
The primary α-3’-5’-cyclic monophosphate antibody was conjugated to BioMag® 
Amine-terminated beads (50 mg/mL) as directed by the provided protocol (Polysciences, 
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Inc). Lyophilized antibody was reconstituted in distilled water to a final concentration of 0.5 
mg/mL, and dialyzed in coupling buffer (0.01 M pyridine in distilled water, pH 6.0), 
changing the buffer three-times over a 9 hr period. The beads then were prepared by washing 
with coupling buffer, and magnetically separating three times. Glutaraldehyde solution (5% 
glutaraldehyde in coupling buffer) was mixed with the BioMag® beads, and reacted for three 
hours with rotation. The beads were washed four times with coupling buffer, and antibody 
was added to the beads with rotation for 16-24 hrs. Glycine quenching solution (1 M glycine, 
pH 8.0) was combined with beads and rotated for 30 min. Primary α-cAMP-beads were 
mixed a volume of 20 mL of storage buffer (0.01 M Tris, 0.1% NaN3, 0.1% w/v BSA, 0.15 
M NaCl, 1 mM EDTA, pH 7.4), and stored at 4°C. The antibody-bead conjugate was used 
for up to three months with no appreciable sign of degradation. Fidelity of the conjugate was 
assessed by determining the ratio of binding between two sets of tubes, one containing 
radiolabeled cAMP bound to primary antibody and the other containing only radiolabeled 
cAMP. A ratio of 0.2-0.3 was found to be ideal while less than 0.2 led to inconsistent 
replicates. 
Radioimmunoassay 
cAMP standards (2 nM-500 nM) and sample aliquots (5 µL) were transferred from 
the 48-well microplate in which the cAMP formation was performed to 96-well Skatron 
plates containing Macrowell tube strips. Sodium acetate buffer (50 mM, pH 6.75) was added 
to the sample wells to bring the total volume up to 50 µL. Samples that contain cAMP 
outside of the range of the standard curve can be diluted with additional sodium acetate. An 
acetylating mixture of TEA/AA (2:1 ratio) was added (5 µL) to the wells and vortexed. 
Acetylation increases assay sensitivity presumably by creating a structure that more closely 
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resembles the original hapten. 125I-cAMP was then added within 30 minutes of acetylation. 
Optimal ranges for radioactivity were determined to be between 280 cpm/µL to 320 cpm/µL 
for iodinated 125I-cAMP-scTME. An aliquot (20 µL) of conjugated-primary antibody then 
was added to bind labeled and unlabeled cAMP (in 50 mM sodium acetate, 0.1% BSA, pH 
4.75). Plates were incubated overnight at 4°C. Radioimmunoassay reactions were terminated 
by filtration with UniFilter-96 plates (Perkin-Elmer) with dH2O. Plates were washed three 
times and then dried at 50°C for 1 hour. Microscint™ 20 fluid (50 µL) was added to the 
wells, and counted on a TopCount NXT (Perkin-Elmer) for 2 min or 2σ = 5%.  
Data Analysis 
Standard data were fit to a one-site binding competition model using Prism 4 
(GraphPad Inc, San Diego CA USA). Sample data were fit by interpolation using standard 
data to obtain fmol cAMP values. A sigmoidal regression model was used to fit the data to 
obtain EC50 and maximal efficacy values over the complete dose range (10-4-10-10 M).  
DISCUSSION 
It should be underscored that the radiosynthesis of the marker does not require a UV 
detector or radioactivity detector to perform this separation, as a lab radioactivity monitor can 
easily distinguish the tubes that contain the desired material. Moreover, although we use a 
dedicated HPLC system for this work, the separation could be optimized for a SepPak, 
although the disadvantage is that it is difficult to verify the separation. This would not save 
significant time, but does not require a dedicated “hot” HPLC.  
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Elimination of secondary antibody allows direct detection 
All prior procedures have used secondary antibodies to separate free and antibody-
bound 125I-cAMP-ScTME after the incubation of the analytical samples with the primary 
antibody. Techniques have included ammonium sulfate precipitation (Steiner et al., 1972), 
charcoal-albumin (Harper and Brooker, 1975), and more recently, polyethylene glycol-
assisted secondary separation of bound and unbound 125I-cAMP (Amersham Biosciences) in 
which samples are pelleted by centrifugation, excess fluid in each tube decanted or aspirated, 
and bound radioactivity quantified. Subsequent modifications of this method have used 
secondary antibody conjugated to magnetic beads for detection of cAMP. All of these 
procedures are relatively laborious and we therefore examined whether both cost and time 
savings might result from elimination of the use of secondary antibody. We hypothesized that 
the primary antibody could be conjugated directly to Biomag® amine-terminated beads (see 
Materials and Methods), and then used in a one-step assay. We therefore used the beads 
prepared as described above.  
To expedite the radioimmunoassay (RIA), we attempted to eliminate the use of 
secondary antibody by conjugating anti-succinyl-cAMP antiserum to Biomag® amine-
terminated beads (see Materials and Methods). Following the conjugation of antiserum to 
Biomag® beads, we compared the ability of cAMP antiserum to bind cAMP standards. After 
incubation, the free radiomarker and that bound to the primary antibody-conjugated BioMag® 
beads were separated using a 96-well harvester and UniFilter-96 GF/B plates (1 µm pore 
size, PerkinElmer), thus enabling detection of bound radioactivity using a high throughput 
plate counter (Perkin-Elmer TopCount NXT). Samples (10 µL) were transferred to 
Macrowell tube strips (using a 12-channel electronic pipette) and necessary reagents were 
added as described in the Experimental Procedures section. Following overnight incubation 
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with 30 µL of primary antibody (1:40 dilution), samples were harvested using Filtermate 
Harvester (Packard) and plates were dried for ~1 h. Scintillation fluid (50 µL) was added to 
each well, and plates were counted on a TopCount NXT. Cross-well variation was corrected 
for following the manufacturer’s protocol. Not only does this result in useful standard curves, 
but application to a well-characterized system (the dopamine D1 receptor) results in EC50 
values consistent with earlier literature. My results demonstrate that cAMP antiserum 
conjugated to beads can be used to separate bound and free 125I-cAMP with the method of 
separation utilized in this study.  
Optimization of cAMP antiserum conditions 
To determine optimal conditions for cAMP antiserum binding, we assessed the ability 
of the antibody to bind cAMP under variable assay conditions. cAMP standards were 
incubated with antiserum volumes of 50 µL and 10 µL (1:40 dilution in 50 mM sodium 
acetate, pH 6.75) for 2 h at room temperature, and overnight at 4ºC. All assay conditions 
yielded viable standard curves (Figure 2.3). As anticipated, the total amount of cAMP bound 
was greater for samples incubated with a 50 µL volume of cAMP antiserum than samples 
incubated with 10 µL. Incubation overnight resulted in increased levels of binding for both 
dilutions compared to the samples incubated for 2 h at room temperature. These results 
indicate that antiserum conditions (i.e. dilution, volume, and time of incubation) can be 
altered according to individual preference and assay requirements. For future experiments we 
chose to use an overnight incubation using 30 µL (per well) of cAMP antiserum at a 1:40 
dilution. 
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Figure 2.3. cAMP standard curves generated under varying assay conditions. Standards were 
incubated for 2 hrs. at room temperature with 50 µL (A) and 10 µL (B)  primary antibody and 
overnight at 4 C [50 µL (C), 10 µL (D)]. Each assay condition yielded a viable standard curve, 
indicating that the conditions can be tailored according to the user’s needs. 
Assay precision and accuracy 
To assess the feasibility of this new cAMP method, we performed an RIA using assay 
conditions as described by Amersham and our new method. The adenylate cyclase portion of 
the assay was conducted as described in the Experimental Procedures section. Samples were 
drawn from the same adenylate cyclase plate and cAMP concentrations were measured using 
both RIA methods. We determined that the efficacy (Figure 2.4) and potency of dopamine 
and SKF38393 was the same for the old method and our new method (Figure 2.4). In light of 
the fact that some assays are limited by their ability to distinguish full and partial agonists 
(Williams, 2004), it is noteworthy that our method easily detects compounds with partial 
agonist activity (e.g., SKF38393).  
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Figure 2.4. Measurement of D1 dopamine receptor-mediated cAMP accumulation utilizing [Left 
panel] secondary antibody-PEG assisted RIA method, and [right panel] our new RIA method 
(primary antibody conjugated to beads. cAMP production was measured using HEK293 cell 
membranes transiently expressing human D1 dopamine receptors. Data are expressed as % maximal 
cAMP stimulation caused by dopamine. The curves shown represent mean + SEM for quadruplicate 
determinations of cAMP accumulation from four separate experiments. 
To assess the between-assay reproducibility for our method we pooled the standard 
deviation of duplicate samples for twenty assays (Figure 2.5). The Coefficient of Variation 
(CV) ranged from 7-13%, with the CV being 10% or less over a dynamic range of more than 
two orders of magnitude. This is an acceptable figure for an assay based on protein binding 
that uses radioactivity as its endpoint. It should be noted that a significant portion of the 
experimental variance is due to counting error (Mailman and Boyer, 1997; Motulsky, 2007), 
a factor that can be decreased by longer counting times if desired. It is known that this assay 
employs very good precision, and these data also show that it has good accuracy, both of 
which could be improved by longer counting time at the tradeoff of throughput.  
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Figure 2.5. Precision profile demonstrates the Coefficient of Variation as a function of the 
concentration of cAMP standards.  
Cost issues and alternative technology 
In this study we have demonstrated an improved method of cAMP detection that 
allows for the quick, accurate measurement of femtomole levels of cAMP. A flowchart of 
this method is shown in Figure 2.6. We have eliminated the need for secondary antibody and 
time-consuming separation techniques. By altering the mode of detection and assay format, 
we have increased throughput and excluded laborious steps inherent to the previous method. 
Although our research focus is on whole-cell and membrane assays of Gαs/OLF, Gαi/o and 
Gαq/11 coupled GPCRs, the method is applicable to any measurement of cAMP and can be 
easily adapted for cGMP. 
The method summarized in Figure 2.6 significantly reduces the costs required to 
perform the assay. Modification of the assay format and method of detection has yielded a 
substantial reduction of the time, labor, and costs, as well as a decrease in reagents used for 
the previous method. At the time of submission of this manuscript, [125I]cAMP-ScTME cost 
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$1,517 for 50 µCi (Perkin Elmer; NEX130050). Reagents suitable for dozens of 
radioiodinations cost less than $200, and 5 mCi of Na125I can be purchased from Perkin 
Elmer for $155 yielding a total cost of finished product for a single iodination of < 
$100/mCi, several-hundred-fold less than the commercial cost.  
1. Assay (Source of Samples)
2. cAMP Acetylation
3. cAMP Radioimmunoassay
4. Filtration (Cell Harvester)
5. Quantification (Counter)
125I-cAMPscTME
Conjugated anti-cAMP
 
Figure 2.6. Schematic flowchart of the described method.  
For the overall assay system we estimate our cost to be ca. $0.50/sample, several-fold 
less expensive than competing commercial systems. For example, one commercial ELISA 
assay costs $310 for a single 96 well assay plate, and also has a sensitivity of at least an order 
of magnitude less than the method we describe. Protein binding assays have also been used in 
the assay of cAMP for decades (Brown et al., 1972; Ekins and Brown, 1972). Such protein 
binding assays are fast and suitable for high throughput, but are of much lower sensitivity, 
and also require preparation of the cAMP binding protein preparation and the use of a long-
lived relatively expensive radioactive marker (i.e., 3H-cAMP). Finally, it should be obvious 
that this method could be easily adapted to the radioimmunoassay of cGMP. Indeed, the 
general approach used can also improve the throughput of any radioimmunoassay. 
  
CHAPTER 3.  
D1 RECEPTOR STIMULATION ACTIVATES ADENYLATE CYCLASE BUT 
NOT PHOSPHOLIPASE C 
ABSTRACT 
Previous reports indicate the phenylbenzazepine SKF83959 via D1-like receptors 
selectively activates phospholipase C, but not adenylate cyclase. In addition, another 
phenylbenzazepine, SKF83822, is purported to signal exclusively through adenylate cyclase, 
as opposed to phospholipase C. Based on these observations, our present study characterized 
several families of D1 agonists to assess the existence of functionally selective properties at 
D1 receptors. Competition binding and functional assays (inositol phosphate formation, 
cAMP generation) were used to assess the differences. SKF83959 mediated adenylate 
cyclase activation, showing partial agonist activity in both transfected HEK293 cells and rat 
striatal tissue. None of the D1 agonists tested was observed to induce inositol phosphate 
generation. Conversely, activation of muscarinic receptors with carbachol showed the 
expected increase in PLC activity, indicating that this signaling system was functional in our 
assay systems. Our results show, in contrast to previous reports, that SKF83959 stimulates 
adenylate cyclase and not phospholipase C. Furthermore, we found no significant PLC 
activation for any of the D1 agonists tested.  
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INTRODUCTION: 
D1-like dopamine receptors, part of a family of proteins termed G protein coupled 
receptors (GPCRs), are characterized by their ability to stimulate adenylate cyclase via Gαs/olf 
coupling (Brown and Makman, 1972; Herve et al., 1993). Several studies have suggested, 
however, that D1 receptors may also couple to Gαq/11, and thus activate phospholipase C 
(Felder et al., 1989a; Jose et al., 1995; Wang et al., 1995; Yu et al., 1996; Zhen et al., 2005). 
The possibility of concurrent coupling of the D1 receptor to Gαq/11 and Gαs/olf, together with 
prior evidence of agonist-induced preferential G protein coupling, opens the door to studying 
important mechanistic questions about functional selectivity (Urban et al., 2007a). 
Early studies used the 6-OHDA lesioned rat model utilized SKF83959 to assess both 
behavioral endpoints and cAMP generation in striatal tissue. Gnanalingham et al. showed 
that SKF83959 (see Figure 3.1) stimulated adenylate cyclase in a seemingly dose-
independent fashion. Significant stimulation at 10 µM compared to the intact unlesioned side 
was observed, however, at increased concentrations no dose-dependent increase was 
observed. Lesioned rats exhibited pronounced contralateral turning with treatment of 
SKF83959 at the highest concentration of the drugs tested but again, dose-independence 
confounded the interpretation of results (Gnanalingham et al., 1995).  
The hypothesis that SKF83959 selectively activates PLC versus adenylate cyclase has 
largely originated from animal behavioral models. In a study using naïve rats, SKF83959 was 
shown not to induce contralateral turning. Conversely, turning did result when it was 
combined with the D2 full agonist quinpirole. This effect then was blocked by the addition of 
the selective D1 antagonist SCH23390. The authors surmised the turning phenotype was due 
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to the D1 selective activation of phospholipase C. In the 6-OHDA rat model, SKF83959 by 
itself induced contralateral turning that was inhibited by SCH23390 (Cools et al., 2003).  
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Figure 3.1: Structures of the phenylbenzazepine SKF83959 and other ligands used in this study. 
Three families of phospholipase C (PLC) have been characterized: PLC-β; PLC-γ; 
and PLC-δ. Upon activation these enzymes hydrolyze phosphatidylinositol 4,5-bisphosphate 
(PIP2) producing 1,2-diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). IP3 binds to 
the IP3 receptor, stimulating the release of Ca2+ from intracellular stores within the 
endoplasmic reticulum while DAG recruits protein kinase C (PKC) to the plasma membrane, 
leading to NF-κB activation and phenotypic changes, such as actin reorganization. IP3 also 
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stimulates the production of inositol 1-phosphate (IP1), which was used as a downstream 
marker of activation for our studies.  
In this study, we demonstrate high affinity binding of ligands from several different 
structural families of D1 compounds. We also show that SKF83959 has partial agonist 
activity at adenylate cyclase using both hD1-HEK293 cell model and caudate rat tissue. A 
significantly greater potency was found in caudate rat tissue, whereas maximal efficacy was 
roughly half that in the HEK293 cell model. In addition, a lack of phospholipase C activation 
was observed for all D1 agonists tested.  
MATERIALS AND METHODS 
Dihydrexidine was synthesized according to procedures published previously 
(Brewster et al., 1990). The D1-selective antagonist [3H]SCH23390 was synthesized 
according to procedures published previously (Wyrick and Mailman, 1985). The compounds 
dopamine, A77636, SKF83822, SKF83959 and SKF38393 and all other reagents were 
purchased from Sigma-Aldrich (St. Louis MO) or Tocris Bioscience (Ellisville MO). 
Cell Culture 
The full length human D1 dopamine receptor cDNA sequence was cloned from a 
human cDNA library, along with the addition of a hemagglutinin (HA) epitope sequence 
(YPYDVPDYA). The primers contained a 5’ KpnI and 3’ XhoI recombination site. This 
sequence was ligated into the pcDNA5/FRT plasmid for transfection into Flp-In TRex 
HEK293 (Invitrogen). The wild-type Flp-In TRex HEK293 cell line was maintained with 
100 µg/mL zeocin and 15 µg/mL blasticidin. These cells were transfected with the HA-hD1-
pcDNA/FRT plasmid using Lipofectamine (Gibco/Invitrogen) and selected using 15 µg/mL 
blasticidin, 200 µg/mL hygromycin in Dulbecco’s Modified Eagles’ Medium, 50 U/mL of 
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penicillin, 50 µg/mL streptomycin (Gibco/Invitrogen), and supplemented with 10% fetal 
bovine serum at 37°C, 5% CO2. Following selection, the HA-hD1-pcDNA5/FRT HEK293 
cells were maintained with 7.5µg/mL blasticidin and 100µg/mL hygromycin. The expression 
of hD1 receptor was titrated with tetracycline (0.05 µg/mL) to controllably induce a receptor 
Bmax of ~5 pmol/mg protein. 
Competition Binding 
Competition binding experiments were performed to assess the affinity (K0.5) of 
SKF83959 and other reference compounds for the hD1 receptor. HA-hD1-pcDNA5/FRT 
HEK293 cell membranes expressing wild-type receptor were incubated with [3H]SCH23390 
(final concentration of 1µM) and varying concentrations of ligand in buffer (50mM HEPES, 
4 mM MgCl2, 0.01% ascorbic acid, pH 7.4 with KOH). Total binding was defined as the 
amount of [3H]SCH23390 bound in the absence of a competing ligand. Non-specific binding 
was determined by binding in the presence of 1µM non-tritiated SCH23390. Experiments 
were setup in triplicate for each assay condition in 96 well plates. Reactions were terminated 
by filtration using a Packard 96 Filtermate Harvester (Packard BioScience Company; 
Meridian, Connecticut). Upon drying the plates at 50ºC for 1 hr, 35 µL of Packard 
MicroScint 20 scintillation cocktail was added to each well. Total CPM was assessed using a 
Packard TopCount NXT Microplate scintillation counter (Packard, Downers Grove, IL).  
cAMP accumulation assay and RIA 
Assay buffer was prepared containing 100 mM HEPES, 4 mM MgCl2, 2 mM EDTA, 
100 mM NaCl, 10 µM pargyline, 500 µM IBMX, 0.1% ascorbic acid, pH 7.4. Drug dilutions 
were prepared at a range of 10-5 to 10-11 M with three replicates per drug treatment. Diluted 
drugs, 2 mM ATP, 5 µM GTP, 20 mM phosphocreatine, 185 U/tube creatine phosphokinase 
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and 100 µM propranolol (to block endogenous β1-adrenergic receptors) were added in a total 
volume of 100 µL in each well of a 48-well plate. The reaction was initiated by addition of 
hD1-HEK293 cell membranes. Plates were then vortexed briefly an incubated at 30°C for 15 
min. The reaction was terminated with 500 µL 0.1 M HCl and stored at 4°C. Prior to 
transferring samples for the RIA, plates are spun down for 5 min at 3200 rpm using a RC-3B 
refrigerated centrifuge from Sorvall Instruments (H2000B rotor) to pellet cellular debris. 
Plates will keep indefinitely at 4°C following the assay. Where rat caudate tissue was needed, 
the protocol was the same as above with the addition of adenosine deaminase (1 U/mL) and 
specific antagonists to block off-target receptor activation: ketanserin (100 µM), yohimbine 
(10 µM), haloperidol (10 µM), prazosin (10 µM) and propranolol (10 µM).  
Sample aliquots were taken from the cAMP accumulation plates, in addition, cAMP 
standards were added to the 96-well RIA plates. Sodium acetate (50 mM, pH: 4.75) was 
added, followed by a mixture of triethylamine/acetic anhydride (2:1). Plates were vortexed 
and [125I]-cAMP-ScTME added (28-30,000 DPM/50 µL) followed by anti-cAMP primary 
antibody diluted at 1:40 (in 1% BSA solution). Plates were incubated overnight at 4ºC. 
Biomagnetic particle (BMP) anti-Goat IgG [H&L] (Rockland, Gilbertsville, PA) were added 
and incubated for 1 hr at 4ºC. Plates were filtered using a 96-well plate harvester (Packard 
Filtermate 196) with ice cold acetate buffer (Harper and Brooker, 1975). 
PLC assay 
The IP-One assay was used to determine inositol phosphate stimulation. (Cisbio, 
Bedford, MA). In HA-hD1-pcDNA5/FRT HEK293 cells, 96-well plates (pre-treated with 
poly-L-lysine) were seeded at 50,000 cells/well and incubated overnight. Drug dilutions were 
performed in stimulation buffer (10 mM HEPES, 1 mM CaCl2, 0.5 mM MgCl2, 4.2 mM KCl, 
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146 mM NaCl, 5.5 mM Glucose, 50 mM LiCl pH: 7.4) and added to the plates, which were 
incubated for 1 hr at 37ºC, 5% CO2. Cells were then incubated in lysis buffer for 30 min. 
Samples were transferred to the IP-One ELISA plate in addition to IP-1 standards, α-IP-1 
mAb, and competitive IP1-HRP conjugate. The plate was incubated for three hours at room 
temperature followed by three washing steps. The colorimetric reaction was completed by 
addition of TMB (tetramethylbenzidine), incubated for 30 min, and terminated with stop 
solution. The 96-well plate was read at 450 nm/620 nm using a Vmax plate reader (Molecular 
Devices, Sunnyvale, CA).  
Data Analysis 
Competition binding and cAMP accumulation data were analyzed using sigmoidal 
nonlinear regression with a variable slope dose-response fit, yielding IC50 or EC50 values and 
Hill slopes values. Values for K0.5 of the compounds were calculated from the IC50 derived 
from regression analysis (Cheng and Prusoff, 1973). Data are expressed as means ± SEM. 
One way ANOVA was used to assess significance for potency and intrinsic efficacy between 
rat tissue and human cell models. Adenylate cyclase data were expressed relative to the 
percentage of cAMP produced by 10 µM dopamine. 
RESULTS 
Competition binding was used to assess D1 receptor binding with the high affinity 
antagonist [3H]SCH23390. The rank order potency for the compounds tested was SKF82957 
= SKF83959 > A77636 > DHX > SKF83822 = SKF38393 > SKF81297 > dopamine. The 
apparent affinity constant, K0.5, values can be seen in Table 3.1. D1 receptor expression was 
titrated in pcDNA5-HEK293 cells with tetracycline to controllably induce a receptor Bmax of 
~5 pmol/mg protein. Non-linear binding curves can be seen in Figure 3.2.  
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Table 3.1: Competition binding of high affinity D1 compounds 
Ligand K0.5 (nM) Hill slope 
Dopamine  814 ± 1  -0.79 ± 0.08 
SKF83959  1.9 ± 1.1  -0.88 ± 0.07 
DHX  4.5 ± 1.2  -0.93 ± 0.16 
SKF38393  12.4 ± 1.1  -0.85 ± 0.06 
SKF81297  13.5 ± 1.2  -1.07 ± 0.13 
SKF82957  1.0 ± 1.2  -0.87 ± 0.09 
SKF83822  12.3 ± 1.2  -0.84 ± 0.09 
A77636  2.4 ± 1.2  -0.92 ± 0.13 
K0.5 values calculated from IC50 determination using variable slope non-linear regression (Graphpad Prism 4). 
Results are from three independent experiments performed in triplicate with ± SEM shown. 
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Figure 3.2: Competition binding of compounds in hD1-HEK293 cells. Results are from three 
independent experiments performed in triplicate with ± SEM shown. 
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Figure 3.3: Adenylate cyclase activation in stable HA-hD1-HEK293 cells. Non-linear regression 
curves were used for best fit to obtain potency (EC50) and intrinsic activity value. Data are expressed 
as % maximal stimulation by 10 µM DA Data are representative of 3 independent assays run in 
triplicate and each value represents the mean + S.E.M.  
 
 41 
Caudate rD1
(partial agonists)
-12 -11 -10 -9 -8 -7 -6 -5 -4
0
10
20
30
40
50
60
70
80
90
100
110
120
SKF83959
SKF38393
SKF83822
Log [DRUG]
%
 
 
M
ax
 
DA
Caudate rD1
(full agonists)
-12 -11 -10 -9 -8 -7 -6 -5 -4
0
10
20
30
40
50
60
70
80
90
100
110
120
DA
A77636
DHX
Log [DRUG]
%
 
M
ax
 
D
A
 
Figure 3.4: Adenylate cyclase activity in caudate tissue from Sprague-Dawley male rats. Non-linear 
regression curves were used for best fit to obtain potency (EC50) and intrinsic activity value. Data 
are expressed as % maximal stimulation by 10 µM DA Data are representative of 3 independent 
assays run in triplicate and each value represents the mean + S.E.M. 
 
 
SKF83959 potently stimulates adenylate cyclase in HEK293 and rat caudate tissue 
As Table 3.2 shows, SKF83959 is highly potent and exhibits partial agonist activity at 
both the human D1 receptor and rat striatal tissue. Figure 3.3 shows partial and full agonist 
activity in HEK293 cell and Figure 3.4 shows similar results in rat caudate tissue. The 
intrinsic activity of SKF83959 showed an increased trend in HEK293 cells indicating either 
differential signaling within the rat caudate gross tissue or changes in maximal efficacy for 
the rD1 receptor. SKF83822 was found to be one order of magnitude less potent in caudate 
tissue. The remaining compounds tested did not show marked differences for intrinsic 
activity or potency. A77636 and DHX showed full agonist activity in both systems, as 
expected. Intrinsic activity values are represented as % maximal stimulation of dopamine at a 
concentration of 10 µM. 
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Table 3.2. Adenylate cyclase activation by key ligands.  
 
hD1-HEK293 cells Rat caudate tissue 
Compound 
Potency (nM) Efficacy (% DA) Potency (nM) Efficacy (% DA) 
SKF83959 3.4 ± 0.33 47.1 ± 4.7 0.26 ± 0.56 27.7 ± 2.3 
SKF83822 85.6 ± 0.25 63.2 ± 3.0 8.3 ± 0.13 67.2 ± 3.2 
A77636 8.0 ± 0.16 96.8 ± 4.6 6.0 ± 0.17 81.7 ± 3.4 
SKF38393 15.8 ± 0.26 42.7 ± 4.7 15.2 ± 0.23 43.5 ± 3.0 
DHX 8.5 ± 0.18 81.9 ± 4.9 18.4 ± 0.23 76.6 ± 5.5 
Data represent the means ± SEM (in nM and % maximal dopamine stimulation) from three 
independent experiments performed in triplicate.  
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Figure 3.5: IP1 stimulation via phospholipase C in HA-hD1-HEK293 cells. IP1 was used as a 
surrogate for IP3 generation. Carbachol was used as a positive control and indicated the PLC 
pathway was intact. Dose-response curves were generated using 7-8 concentrations of test 
compounds. Non-linear regression curves were used for best fit to obtain potency (EC50) and 
intrinsic activity value. Data are expressed as % maximal stimulation by 10 µM DA. Data are 
representative of 3 independent assays run in triplicate and each value represents the mean + S.E.M. 
D1 receptors do not stimulate IP-3 formation in vitro 
Using carbachol as a positive control for phospholipase C, several D1 agonists were 
tested for IP1 formation in an in vitro hD1-HEK293 cell model (Figure 3.5). Dopamine, 
SKF83959, SKF83822, dihydrexidine and A77636 did not exhibit potent stimulation as 
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compared with stimulation of endogenous muscarinic receptors with carbachol. To insure 
that PLC machinery is intact within the hD1-HEK293 cells, we used ATP stimulate 
endogenous adenosine receptors in order to produce a positive response (data not shown). 
IP1, a downstream metabolite of IP3, is used as a surrogate marker of activity for IP3 
stimulation. Activation of PLC is mediated via Gαq/11 and has been putatively linked to the 
D1 receptor, however, these results suggest no PLC activity mediated by the D1 receptor. 
Figure 3.6 shows treatment with dopamine alone and dopamine blocked with the specific D1 
antagonist SCH23390. This reinforces the inability of D1 receptors in mediating PLC 
activity. 
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Figure 3.6: D1 specific antagonist treatment has no effect on PLC activity in hD1-HEK293 cells. 
Dose-response curves were generated using 6 concentrations of DA and DA with 10 µM SCH23390. 
Non-linear regression curves were used for best fit to obtain potency (EC50) and intrinsic activity 
value. Data are expressed as % maximal stimulation by 10 µM DA. Data are representative of 3 
independent assays run in triplicate and each value represents the mean + S.E.M. 
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DISCUSSION 
My data show that the D1 receptor appears not to signal through phospholipase C, and 
indeed, that SKF83959 specifically has no such activity in contrast to previous studies (Jin et 
al., 2003; Yu et al., 1996). Other studies of phenylbenzazepine compounds led to the 
hypothesis, alternatively, of the existence of a novel “D1-like” phospholipase C-coupled 
receptor (Friedman et al., 1997; Undie et al., 1994). These reports found potency values for 
phosphoinositide hydrolysis to be in the 1 mM-100 µM ranges. With such low potency, the 
possibility of an off-target action is a clear possibility that has not been adequately addressed. 
These earlier reports also noted that some phenylbenzazepine compounds that stimulated 
PLC, but not cyclase, as well as vice versa (Jin et al., 2003; Yu et al., 1996). Experiments 
have shown that knockout of D1 receptors abolishes the cyclase activity of the partial agonist 
SKF38393, yet not affecting SKF38393-induced inositol phosphate (IP) accumulation 
(Friedman et al., 1997). The generation of IP was found only at very high concentrations of 
agonist, suggesting to us that this effect was likely due to off-target effects. The hypothesis 
that there is an new “D1-like” PLC-coupled receptor is further weakened by any of the 
orphan GPCRs in the human or mouse genome have characteristics compatible with a D1-
like identity. 
The current studies show that SKF83959 has partial agonist properties at adenylate 
cyclase, contrary to our data that characterized its PLC activity. Although there are 
differences in intrinsic activity between the human D1 receptor expressed heterologously and 
the rat striatal D1 receptor in situ, this probably reflects the receptior reserve and other 
aspects of the signaling pathways, and not functional selectivity of this ligand. It is 
reasonable to assume that a myriad of other scaffolding proteins, RGS proteins, and various 
heterotrimeric G proteins are found in the gross tissue sample used for my analysis. The 
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human D1 and rat D1 receptor show 94% homology (Li et al., 2004), and in addition a 
thorough examination of NIMH Psychoactive Drug Screening Program database shows 
minimal differences in binding profiles between the two species’ receptors (Roth, 2008). It is 
interesting that increased potency is found in rat caudate tissue where D1 receptor expression 
is at least one order of magnitude lower than in HEK293 cells (data not shown). One would 
expect increases in potency in populations with higher receptor expression, assuming the 
receptor:G Protein:effector stoichiometry remains the same. The possibility remains, 
however, that drug-specific differences in potency and efficacy exist, but this remains to be 
proven.  
Evidence for a cAMP/PKA-independent signaling pathway can be found in studies 
with adenylate cyclase V deficient mice (Iwamoto et al., 2003; Lee et al., 2002). While 85-
90% of cyclase activity is abrogated, locomotion is enhanced. It is not clear from this study, 
however, whether the behavioral effects are due to a non-cyclase dependent PLC pathway. 
My results clearly show intact cAMP signaling and hence PKA activation but no PLC 
response. Thus, in the hD1-HEK293 cell model, it seems clear that PLC activation is not 
dependent on PKA.  
Another interesting phenylbenzazepine compound, SKF 83822, has been reported to 
exhibit functionally selective properties. Authors describe the compound as having the 
opposite signaling properties of SKF83959, that is, stimulating adenylate cyclase while 
having antagonistic properties for phospholipase C. Behavioral models linked to different 
signaling pathways were used to distinguish the functionally selective properties of the 
compounds tested (O'Sullivan et al., 2004). My study also contradicts the finding showing 
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that SKF 83822 indeed has no PLC activity, but is a partial agonist for AC, albeit with 
lessened potency. 
A potential limitation of my work is the use of IP1 as a surrogate marker for IP3. The 
short-lived existence of IP3 (~ 30 sec) makes reliable quantification difficult. On the other 
hand, previous work with Gαq-coupled receptors demonstrated that IP1 is an excellent 
surrogate for IP3 formation (Trinquet et al., 2006). Consistent with this, PLC activation by 
carbachol and ATP lead to IP1 generation that is proportional to the formation of IP3. Thus, 
this is unlikely a confound in the current experiments. 
Several studies have shown concurrent Gαq/11 and Gαs/olf coupling to the D1 receptor 
(Mannoury la Cour et al., 2007; Panchalingam and Undie, 2000; Wang et al., 1995), and 
some reports indicate differential coupling upon addition of SKF83959 (Rashid et al., 2007). 
All four members of the Gαq/11 family (αq, α11, α14, α16) have been shown to activate PLC-β 
isoforms, but not PLC-γ, PLC-δ or PLC-ε (Hepler et al., 1993; Kozasa et al., 1993; Lee et al., 
1992). There is clear evidence from other receptor systems, namely the A1 adenosine 
receptor, that agonists can induce specific receptor conformations leading to selective 
activation of Gs, Gi, or Gq proteins (Cordeaux et al., 2004). Other examples of such 
functional selectivity are plentiful (Berg et al., 1998; Bonhaus et al., 1998; Brink et al., 2000; 
Gazi et al., 2003; Harikumar and Chattopadhyay, 1999) as has been recently reviewed 
(Urban et al., 2007a). 
The existence of agonist specific conformational states is central to the idea of 
functional selectivity. Panchalingam and Undie discovered D1 receptor selective G-protein 
activation in striatal membranes using the following compounds: SKF38393 (Gq/Gs), 
SKF85174 (Gs), and SKF83959 (Gq). Furthermore, the addition of deoxycholate was used 
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with the intent of changing membrane dynamics (and thus the receptor conformation) in such 
a way that Gq/PLC was favored over Gs/adenylate cyclase signaling (Panchalingam and 
Undie, 2005). The use of deoxycholate, while useful in demonstrating the possibility of 
selective Gq-coupling, does not suggest probable G protein coupling to the D1 receptor in 
vitro or in vivo.  
Early evidence has suggested SKF82526, a D1 full agonist, stimulates PLC in rat 
renal cortical membranes (Felder et al., 1989b). This effect was blocked by the selective D1 
antagonist SCH23390, whereas the α-adrenergic antagonists prazosin and phentolamine had 
no effect. Additionally, the D2 agonist LY 171555 did not induce IP release. The signaling 
properties of renal cortical membranes may be similar to my HEK293 cell model, yet we find 
no evidence of IP release. 
When assessing functionally selective compounds, it is crucial to identify 
independent signaling pathways, a task that has been problematic in D1 receptor models due 
to the dearth of widely accepted effector pathways. The “gold standard” effector pathway for 
the D1 receptor, adenylate cyclase, stimulates protein kinase A (PKA), which interestingly 
has been shown to be activated by PLC (Yu et al., 1996). However the dominant PLC 
isoform thought to be involved, PLC-β2, is not expressed in the cell model used (LTK- cells). 
PLC-γ was found to be responsible for the observed activity. Therefore, the model system in 
question may not be predictive of all PLC-β2 expressing systems. A recent study on 
intracellular Ca2+ currents supported the idea of Gαq-mediated PLC activation, however, this 
mechanism was found to be co-dependent on a PKA-cAMP signal (Dai et al., 2008). These 
studies do confound results, as measurements of downstream targets are subject to positive 
and negative feedback inputs (i.e. PKA-mediated phosphorylation of IP3R). It should be 
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noted that the measurement of intracellular Ca2+ currents is not necessarily directly 
translatable from PLC stimulation. Similar data have been found in other studies. Thus, there 
is a strong possibility that a non-PLC Ca2+ mechanism exists (Lin et al., 1995).  
Intracellular calcium release is a critical and seemingly ubiquitous effector, which is 
released upon activation of the IP3 receptor at the ER. Studies in primary cultures of 
neocortical and hippocampal cells have demonstrated that intracellular calcium may be 
released with treatment of D1/D5 agonists, however, this was found to be dependent on 
priming from other Gαq/11-linked receptors such as glutamine, serotonin, muscarinic and 
adrenergic receptors. Not surprisingly, forskolin stimulation of cAMP alone was not 
sufficient to induce intracellular calcium release (Lezcano and Bergson, 2002). Additionally, 
the authors found that D1/D5 mediated calcium release was not observed in striatal tissue.  
Phospholipase C may be activated by both Gαq and Gβγ; while in vitro studies 
indicate high potency activation of PLC by Gαq its clear that Gβγ still plays a role. PLC-β has 
distinct sites for Gαq and Gβγ activation and thus can be synergistically activated (Runnels 
and Scarlata, 1999). The composition of specific Gβγ subunits appears also to affect its 
potency for PLC-β (Boyer et al., 1994). This potential Gβγ-mediated regulation by not only 
D1-like receptors, but among GPCR signaling tone, further complicates interpretation.  
While my work has focused on PLC activation in an in vitro D1 signaling model, it is 
possible that these results do not translate to in vivo conditions in which other signaling 
attenuation and a multitude of neuron-specific scaffolding proteins exist. As mentioned 
earlier, primary cultures of neocortical and hippocampal cells have shown specific conditions 
under which D1-like receptor agonists can induce [Ca], and it is possible this either mediates 
or reflects phosphoinositide signaling. Scaffolding proteins also may play a role in 
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facilitating D1 receptor signaling. One example is β-arrestin 2; traditionally thought of as 
playing a role in GPCR desensitization, it has been found to signal through Akt and PP2A, 
bypassing Gα signaling mechanisms (Beaulieu et al., 2005). This G protein-independent 
mode of signaling provides a new way of understanding the complex interactions among 
signaling partners, its potential role in prolonged stimulation of receptors, warrants further 
analysis.  
In summary, we find no evidence of PLC activation by D1-like receptors, however, 
this assessment was performed in vitro. Previous reports of inositol phosphate generation 
have largely been demonstrated in rat tissue samples; however, with reported EC50’s in the 
millimolar to micromolar range, in vivo PLC activation may not be physiologically relevant. 
The possibility has been raised of the need for priming by Gαq-coupled receptors and 
subsequent stimulation with D1 agonists. This remains to be seen in the context of D1-like 
receptor activation and thus further work is needed. As noted earlier, validation of 
independent signaling pathways is a necessary step in facilitating the study of functionally 
selective compounds, and further studies must decipher the involvement of cAMP-
independent calcium release, ion channel activation and GRK phosphorylation.  
 
  
CHAPTER 4: SUMMARY OF FINDINGS AND FUTURE DIRECTIONS 
SUMMARY OF FINDINGS 
Parkinson’s disease is thought to affect anywhere from 500,000 to 1 million people 
every year in the US, assuredly more throughout the world. The etiology of the disease 
remains elusive for the vast majority of non-familial cases although we gain better 
understanding everyday of dopaminergic signaling. The studies in this thesis offer a better 
understanding of D1 receptor effectors in two ways, by showing negative evidence of PLC 
activation via D1 mechanisms and also by demonstrating specific differences in signaling 
between rat striatal tissue and the hD1-HEK293 cell model.  
Critical to the understanding of functional selectivity is that multiple functional 
pathways couple to the receptor, allowing both differential potencies and intrinsic efficacies. 
The D1 dopamine receptor has of course been long known to couple to adenylate cyclase, 
however, other than GPCR internalization mechanisms, there is a dearth of other independent 
functional pathways known to couple to it.  
Treatment for Parkinson’s disease is fundamentally based on either dopamine 
replacement therapy, or the use of other drugs designed to augment dopaminergic signaling. 
This stresses the need for a more complete understanding of D1 receptor functional pathways. 
As mentioned previously, several studies in the literature suggest that the D1 receptor 
activates phospholipase C. My research indicates that this does not occur, at least in the 
HEK293 in vitro model. Furthermore, we have found that the phenylbenzazepine SKF83959 
does indeed stimulate adenylate cyclase, contrary to reported findings. 
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My phospholipase C results show little to no activation by dopamine and select D1 
agonists. If these results hold true in future studies under in vivo conditions, this would 
sharpen understanding toward the development of D1 agonists; my findings limit PLC-based 
hypotheses that sought to explain therapeutic side effects, or potential exploitation of this 
functional pathway for therapeutic gain. It seems clear that in this model PLC is not 
dependent on the cAMP/PKA pathway.  
Given that Gαq coupling to D1 has only been demonstrated in rat neuronal tissues and 
that PLC signaling is intact in HEK293 cells, it seems likely that two possibilities exist. 
Firstly, species specific differences within the third intracellular loop of the D1 receptor lead 
to inefficient Gαq coupling in the human form, however this remains to be studied. The 
second possibility is that Gαq activation requires priming of Gαq-coupled receptors. This 
observation has been seen in several studies; however, the protein(s) involved have yet to be 
resolved. One report indicated direct interaction between the D1 receptor and calcyon and its 
role in potentiating calcium release, yet this report was retracted when the authors found no 
direct interaction in addition to minimal increases in calcium release when calcyon was 
present (Lezcano et al., 2000).  
FUTURE DIRECTIONS 
Although the hD1-HEK293 cell model is useful for understanding fundamental 
signaling mechanisms, it may be far wide of the mark when attempting to explain the 
dynamics of neuronal signaling. Hence, in recent years, there has been a concerted effort to 
develop cell signaling models that are derived from neuronal cultures and in some cases, 
specific cell types of particular interest. Neurons are highly evolved and complex cell types 
that express a plethora of specific regulatory factors, such as RGS proteins, PSD 
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(postsynaptic density) proteins, and other chaperones, while being dependent on coupling to 
Na+, K+ and Ca+ ion channels to relay action potentials to neighboring post-synaptic neurons. 
This would appear to be the necessary next step in studying PLC dependence on D1 receptor 
activation. Transgenic mouse models are also an important tool to be considered, as in vivo 
D1-mediated PLC activation has not yielded a clear result.  
An important step in determining the mechanisms involved with D1 signaling is a 
better understanding of which G proteins are coupled to the receptor. As noted in Chapter 2, 
previous studies have shown Gαq coupling in rat striatal tissue (Mannoury la Cour et al., 
2007; Panchalingam and Undie, 2000; Wang et al., 1995), however, this has not been 
observed in HEK293 cells. This particular approach has been historically problematic due to 
difficulties in developing epitopes against specific G proteins, leading to high rates of false 
positives.  
Calcium is a dynamic yet tightly regulated second-messenger pathway that is 
controlled differentially across non-nervous and nervous tissue. While the effector may be 
dependent on PLC, there are many other modulating effectors involved. The slow IP3-
mediated pathway via phospholipase C predominates in non-excitable cells. In excitable 
cells, however, voltage-dependent Ca2+ channels (L, N, P/Q type) play a greater role, 
balancing Ca2+ intake/output from the cell. D1-like receptors are positively coupled to L-type 
channels, but negatively coupled to N, P/Q-type Ca2+ channels (Surmeier et al., 1995). The 
mechanism of D1-stimulated inhibition of voltage-gated calcium channels is not entirely 
clear, but appears to be dependent on the PKA/DARPP-32 cascade (Fienberg et al., 1998). In 
a study of prefrontal cortex neurons, D1-stimulated L-type Ca2+ channels lead to PKA-
dependent potentiation and PKC-dependent suppression of currents (Young and Yang, 2004). 
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Thus calcium does not seem to be an appropriate candidate for the study of functional 
selectivity, due to its PKA/PKC dependence.  
G protein-receptor kinases (GRKs) are another viable pathway for study of 
functionally selective compounds due to direct interaction with the receptor. These proteins 
act to phosphorylate GPCRs upon their activation, in turn this leads to desensitization of the 
receptor, preventing further interaction with G proteins. This is the first in a complex series 
of steps leading to GPCR internalization, which may involve arrestins, lipid rafts and 
caveolae. The D1 receptor has been shown to couple to GRK2, GRK3, GRK4, GRK5 and 
GRK6 (Fraga et al., 2006; Tiberi et al., 1996; Watanabe et al., 2002). The theoretical 
possibility remains that different classes of agonists may differentially influence GRK 
interaction with the receptor. Indirect evidence of this phenomenon has been demonstrated 
previously (Ryman-Rasmussen et al., 2007).  
MAP kinase is an important mediator of growth and cell cycle control. Few studies 
have investigated its role in D1-like receptor signaling and such studies are complicated by 
the promiscuity of ERK1/2. Using a catalytically defective form of MEK1, one study 
reported a lack of activation by the D1 partial agonist SKF38393, however, with wild-type 
MEK1, MEK1/2 was selectively activated. Interestingly, p-ERK has been found to form 
stable heterotrimeric complexes with the D1 receptor and β-arrestin 2 (Chen et al., 2004). 
Nagai et al. (Nagai et al., 2007) revealed dose-dependent D1 activation of ERK1/2 in the 
mouse prefrontal cortex that was unaffected by microinjection of a D2 antagonist and blocked 
by a D1 antagonist. The mechanism(s) responsible for D1-MAP kinase activation is unclear, 
but evidence suggests dependence on the β-arrestin scaffolding protein. The D1-MAP kinase 
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pathway shows promise but further studies must be carried out to gain a clearer 
understanding of signaling partners.  
Studies of the D1 receptor do not garner a great deal of attention compared to other 
receptors (D2, β2 adrenergic, etc), hence there is great opportunity to discover novel effectors 
and signaling partners. Given current development of D1 agonists, therapeutic uses in human 
patients will certainly lead to more mechanistic studies. Ultimately, a complete picture of D1 
signaling networks coupled with in vivo understanding should give insight into behavioral 
and therapeutic effects, hopefully leading to the development of D1-specific functionally 
selective drugs with high therapeutic impact and a low side-effect profile.  
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